These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 20068094)

  • 1. NVP-BEZ235 as a new therapeutic option for sarcomas.
    Manara MC; Nicoletti G; Zambelli D; Ventura S; Guerzoni C; Landuzzi L; Lollini PL; Maira SM; García-Echeverría C; Mercuri M; Picci P; Scotlandi K
    Clin Cancer Res; 2010 Jan; 16(2):530-40. PubMed ID: 20068094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
    Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
    Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
    Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T
    Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
    Nanni P; Nicoletti G; Landuzzi L; Croci S; Murgo A; Palladini A; Antognoli A; Ianzano ML; Stivani V; Grosso V; Maira SM; García-Echeverría C; Scotlandi K; De Giovanni C; Lollini PL
    Eur J Cancer; 2010 Feb; 46(3):659-68. PubMed ID: 20031388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
    Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.
    Hernlund E; Olofsson MH; Fayad W; Fryknäs M; Lesiak-Mieczkowska K; Zhang X; Brnjic S; Schmidt V; D'Arcy P; Sjöblom T; De Milito A; Larsson R; Linder S
    Eur J Cancer; 2012 Feb; 48(3):396-406. PubMed ID: 22154651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
    Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
    J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
    Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
    Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
    Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.